Myfembree

Increased risk of thrombotic or thromboembolic disorders. Discontinue immediately if thrombotic, cardiovascular or cerebrovascular event occurs or is suspected or if sudden unexplained loss of vision. Discontinue if gallbladder disease or jaundice occurs, and at least 4–6 weeks prior to surgery associated with increased risk of thromboembolism or during periods of immobilization. Risk of decrease in bone mineral density (BMD). Assess BMD at baseline and periodically thereafter. Consider treatment benefits/risks in those with a history of low-trauma fracture or other risk factors for osteoporosis or bone loss; supplementation with calcium and Vit.D may be beneficial. Perform breast exams and regular mammography. Discontinue if a hormonally-sensitive malignancy develops. Evaluate if new onset or worsening depression, anxiety, other mood changes occur. Monitor BP; discontinue if significant rise occurs. History of cholestatic jaundice associated with prior estrogen use or with pregnancy. Risk of uterine fibroid prolapse or expulsion in women with known or suspected submucosal uterine fibroids. Monitor lipid levels; consider discontinuing if hypertriglyceridemia or hypercholesterolemia worsens. Diabetes. Prediabetes. Hypothyroidism. Hypoadrenalism. Reduced ability to recognize pregnancy. Perform pregnancy testing if suspected; discontinue if confirmed. Advise women of reproductive potential to use effective non-hormonal contraception during and for 1 week after discontinuation. Nursing mothers.

Increased risk of thrombotic or thromboembolic disorders. Discontinue immediately if thrombotic, cardiovascular or cerebrovascular event occurs or is suspected or if sudden unexplained loss of vision. Discontinue if gallbladder disease or jaundice occurs, and at least 4–6 weeks prior to surgery associated with increased risk of thromboembolism or during periods of immobilization. Risk of decrease in bone mineral density (BMD). Assess BMD at baseline and periodically thereafter. Consider treatment benefits/risks in those with a history of low-trauma fracture or other risk factors for osteoporosis or bone loss; supplementation with calcium and Vit.D may be beneficial. Perform breast exams and regular mammography. Discontinue if a hormonally-sensitive malignancy develops. Evaluate if new onset or worsening depression, anxiety, other mood changes occur. Monitor BP; discontinue if significant rise occurs. History of cholestatic jaundice associated with prior estrogen use or with pregnancy. Risk of uterine fibroid prolapse or expulsion in women with known or suspected submucosal uterine fibroids. Monitor lipid levels; consider discontinuing if hypertriglyceridemia or hypercholesterolemia worsens. Diabetes. Prediabetes. Hypothyroidism. Hypoadrenalism. Reduced ability to recognize pregnancy. Perform pregnancy testing if suspected; discontinue if confirmed. Advise women of reproductive potential to use effective non-hormonal contraception during and for 1 week after discontinuation. Nursing mothers.